Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human
InventorsMark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
Estimating the term…
Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.
A method of inhibiting an HIV-1 infection in a subject, comprising administering to the subject an effective amount of a monoclonal antibody, the monoclonal antibody comprising:
A method of inhibiting HIV-1 infection in a subject, comprising administering to the subject an effective amount of an antigen binding fragment of a monoclonal antibody, the antigen binding fragment comprising:
Dependencies are inferred from the claim text.